Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PULSE BIOSCIENCES, INC. (PLSE)

Pulse Biosciences Reaches 164-Patient Enrollment Target in NANOPULSE-AF Study

Neutral Impact 3 of 5 other Written later

Pulse Biosciences said its NANOPULSE-AF pivotal study of the nPulse Cardiac Catheter System for atrial fibrillation reached its enrollment target of 164 evaluable patients across 15 clinical sites. The company said enrollment finished three months ahead of its original 9-month timeline, and primary safety and effectiveness endpoints will be assessed at 6 and 12 months after ablation, so the filing contains no financial results or guidance.

Key points

  • Study reached its target of 164 evaluable patients across 15 clinical sites
  • First patients were treated in April 2026
  • Enrollment finished three months ahead of the original 9-month timeline
  • Primary endpoints will be assessed at 6 and 12 months post-ablation

The filing

CompanyPULSE BIOSCIENCES, INC. (PLSE)
Form8-K, current report
Filed with the SECOct 7, 2026, 9:06 AM ET
Accession number0001437749-26-032271

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.